This study is about corneal crosslinking (CXL), a treatment for eye problems where the cornea (the clear front part of the eye) gets thin and misshaped, causing blurry vision. CXL involves putting vitamin B2 (riboflavin) eye drops on the eye and shining ultraviolet (UVA) light on it, similar to sunlight intensity. This aims to make the cornea stronger and stop the disease from getting worse.
- Participants must be 8 years or older and have specific corneal conditions like keratoconus or ectasia after surgeries like LASIK.
- The study lasts for 6 months with up to 7 office visits for eye tests.
- Participants will be divided into two groups: one receiving 18 minutes of UVA light and the other 24 minutes during the CXL treatment.
Eligible participants must not have certain eye conditions or be pregnant. They should be able to follow the study schedule and agree to use birth control if applicable. The goal is to see if CXL helps prevent vision loss. Participation involves consent and following study guidelines.
How understandable was the trial content above?
Hard to understand
Easy to understand